Oxaliplatin is a very potent platinum (II) drug which is frequently used in poly-chemotherapy
schemes against advanced colorectal cancer. However, its benefit is limited by severe …

The design of targeted platinum (IV) prodrugs is a very promising approach to enhance the
low selectivity of platinum (II) drugs towards cancerous tissue in order to reduce the impact …

Platinum (IV) prodrugs are a promising class of anticancer agents designed to overcome the
limitations of conventional platinum (II) therapeutics. In this work, we present oxaliplatin (IV) …

Cisplatin is a platinum (Pt)-based anticancer drug with broad-scale clinical utility. However,
due to its hydrophilic nature and high kinetic reactivity, it offers numerous drug delivery …

Chemotherapy with platinum complexes is essential for clinical anticancer therapy.
However, due to side effects and drug resistance, further drug improvement is urgently …

Clinically ineffective transplatin is highly potent against cancer cells when transformed into a
transplatin (IV) prodrug nanoparticle. Herein, a hydrophobic transplatin (IV) was synthesized …

Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-
limited due to severe nephrotoxicity. Here we report the rational engineering of a novel …

The approved platinum (II)‐based anticancer agents cisplatin, carboplatin and oxaliplatin
are widely utilised in the clinic, although with numerous disadvantages. With the aim of …

Classical platinum (II) anticancer agents are widely-used chemotherapeutic drugs in the
clinic against a range of cancers. However, severe systemic toxicity and drug resistance …

The efficacy of traditional chemotherapy often suffers from rapid clearance and off-target
toxicity. Drug delivery systems and controlled release are applied to improve the therapeutic …